Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleReviewsR

Potential Anticancer Properties and Mechanisms of Action of Curcumin

NATALIA G. VALLIANOU, ANGELOS EVANGELOPOULOS, NIKOS SCHIZAS and CHRISTOS KAZAZIS
Anticancer Research February 2015, 35 (2) 645-651;
NATALIA G. VALLIANOU
1Evangelismos General Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: natalia.vallianou@hotmail.com
ANGELOS EVANGELOPOULOS
2Roche Diagnostics, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOS SCHIZAS
1Evangelismos General Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTOS KAZAZIS
3Leicester University, Leicester, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Curcumin, a yellow substance belonging to the polyphenols superfamily, is the active component of turmeric, a common Indian spice, which is derived from the dried rhizome of the Curcuma longa plant. Numerous studies have demonstrated that curcumin possesses anti-oxidant, anti-inflammatory and anticancerous properties. The purpose of this review is to focus on the anti-tumor effects of curcumin. Curcumin inhibits the STAT3 and NF-κB signaling pathways, which play key-roles in cancer development and progression. Also, inhibition of Sp-1 and its housekeeping gene expressions may serve as an important hypothesis to prevent cancer formation, migration, and invasion. Recent data have suggested that curcumin may act by suppressing the Sp-1 activation and its downstream genes, including ADEM10, calmodulin, EPHB2, HDAC4, and SEPP1 in a concentration-dependent manner in colorectal cancer cell lines; these results are consistent with other studies, which have reported that curcumin could suppress the Sp-1 activity in bladder cancer and could decrease DNA binding activity of Sp-1 in non-small cell lung carcinoma cells. Recent data advocate that ER stress and autophagy may as well play a role in the apoptosis process, which is induced by the curcumin analogue B19 in an epithelial ovarian tumor cell line and that autophagy inhibition could increase curcumin analogue-induced apoptosis by inducing severe ER stress. The ability of curcumin to induce apoptosis in tumor cells and its anti-angiogenic potential will be discussed in this review.

  • Curcumin
  • anti-cancer properties
  • autophagy
  • transcription factors
  • bioavailability
  • review

Curcumin, a yellow substance belonging to the polyphenols superfamily, is the active component of turmeric, a common Indian spice, which is derived from the dried rhizome of the Curcuma longa plant (1-2). Turmeric contains three principal components, curcumin, demethoxycurcumin and bisdemethoxycurcumin, of which curcumin is the most abundant and potent (3-6). Curcumin comprises approximately 2%-5% of turmeric (7).

Numerous studies have demonstrated that curcumin possesses anti-oxidant, anti-inflammatory and anticancer properties (8-18). Its ability to induce apoptosis in tumor cells and anti-angiogenic potential will be discussed in this review.

Curcumin's Mechanisms of Action: The Role of STAT3 and NF-κB

The nuclear factor (NF)-κB, is a ubiquitous transcription factor that regulates many genes implicated in growth regulation, inflammation, carcinogenesis, and apoptosis (19-20). In vitro and in vivo studies have documented that constitutive activation of NF-κB results in inhibition of chemotherapy-induced apoptosis in a number of cancer cells (21-23). Signal transducer and activator of transcription 3 (STAT3) is a ubiquitously expressed member of the STAT family of transcription factors that is activated by tyrosine phosphorylation via upstream receptors, such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and cytokines, such as interleukin-6 (IL-6) (24). Recent studies have demonstrated that STAT3 may confer cancer resistance to chemotherapeutic agents (25-28).

STAT3 is one of the major mediators of carcinogenesis (29-30). The oncogenic significance of activated STAT3 molecules is due to their effects on various parameters, such as apoptosis, cell proliferation, angiogenesis, and immune system evasion (31, 32). Constitutively active STAT3 has been involved in the induction of resistance to apoptosis, probably through the expression of Bcl-xL and cyclin D1 (33-35). Its role in tumorigenesis is mediated through the expression of genes that suppress apoptosis, mediate proliferation, invasion, and angiogenesis. Constitutive activation of STAT3 has been implicated in a variety of cancers, including breast cancer, prostate cancer, head and neck squamous cell carcinoma, multiple myeloma, lymphomas and leukemia, brain cancer, colon, gastric, esophageal, ovarian, nasopharyngeal and pancreatic cancer (36-47). Nevertheless, it is not completely understood why STAT3 is constitutively active in cancer cells.

Curcumin inhibits the STAT3 and NF-κB signaling pathways, which -as it has already been mentioned- play key-roles in cancer development and progression (48). Constitutive activation of the STAT3 and NF-κB signaling pathways has been demonstrated in prostate cancer cell lines and clinical samples of prostate cancer (49-52).

Curcumin and Other Transcription Factors

Curcumin has also been suggested to induce apoptosis and cause down-regulation of EGFR, Akt, cMET cyclin D1, in CL-5 xenograft tumors (53). In addition, it has been documented to inhibit lung cell invasion and metastasis through up-regulation of HLJ1 expression in cancer cells (54). Apart from its action on STAT3 and NF-κB pathways, curcumin has been shown to inhibit cell proliferation, cell cycle arrest and stimulate apoptosis via modulation of other transcription factors, such as AP-1, Erg-1, p53, β-catenin, Notch-1, Hif-1, and PPAR-α (55).

Curcumin and Sp-1

Sp-1, a transcription factor highly expressed in breast, gastric and thyroid tumor cells compared to normal cells, has been demonstrated to interact with co-activators and co-repressors and, thereby, activate multiple biological functions, including cell cycle and carcinogenesis. It has also been implicated in nuclear factors, protein-protein interaction, and sequence-specific DNA binding (56). Sp-1 has been related to housekeeping gene expression, such as vascular epithelial growth factors (VEGF), urokinase plasminogen activator (uPA), urokinase plasminogen activator receptor (uPAR) and epithelial growth factor receptor (EGFR), which are known to be involved in cell differentiation, tumor angiogenesis and metastasis (57-59). Hence, inhibition of Sp-1 and its housekeeping gene expressions may serve as an important hypothesis to prevent cancer formation, migration, and invasion (60-61). Recent data have suggested that curcumin may act by suppressing the Sp-1 activation and its downstream genes, including ADEM10, calmodulin (CALM), EPHB2, HDAC4, and SEPP1 in a concentration-dependent manner in colorectal cancer cell lines; these results are consistent with other studies, which have reported that curcumin could suppress the Sp-1 activity in bladder cancer and could decrease DNA binding activity of Sp-1 in non-small cell lung carcinoma (NSCLC) cells (62, 63). In addition, curcumin has significantly reduced colony formation in colorectal cancer cells. These results are in agreement with other studies, which have documented that down-regulation of Sp-1 prevents the colony formation in a patient-derived fibrocarcinoma cell line (64).

Curcumin and Adhesion Molecules

Curcumin has been demonstrated to inhibit focal adhesion kinase (FAK) phosphorylation and enhance the expression of several extracellular matrix components, which play a pivotal role in invasion and metastasis. Curcumin has been shown to enhance cell adhesion ability, through induction of extra-cellular matrix components collagen I, collagen III, collagen IV, collagen IX, laminin, and fibronectin in a concentration-dependent manner. Taken together, these results have suggested that curcumin suppresses FAK activity by means of inhibition of its phosphorylation sites and also induces extra-cellular matrix components to enhance cell adhesion ability, thus, preventing detachment of cancer cells and cell migration. Inhibition of FAK expression leads to increased cell adhesion, which may be the potential mechanism of the anti-invasive effect of curcumin (65).

Curcumin has been shown to reduce CD24 expression in a dose-dependent manner in colorectal cancer cells. Moreover, E-cadherin expression has been documented to be up-regulated by curcumin and serve as an inhibitor of epithelial mesenchymal transition. These results suggest that curcumin could exert its function against metastasis, through down-regulation of Sp-1, FAK, and CD24 and by promoting E-cadherin expression in colorectal cancer cells (65). Also, Zhou et al. have evaluated eleven curcumin-related compounds, containing a benzyl piperidone moiety in various cancer cell lines and have found that some of them have been associated with a decrease in phospho-Akt and phospho-extracellular signal-regulated kinase (Erk)1/2 (65).

Curcumin, Endoplasmic Reticulum Stress and Autophagy

Endoplasmic reticulum (ER) is an essential cellular compartment for protein synthesis and maturation. Various pathological conditions may affect ER homeostasis and interfere with protein folding, thus, resulting in an imbalance between ER protein folding load and capacity, leading to the accumulation of un-folded or mis-folded proteins in the ER (66). This cellular condition is widely known as ER stress. Autophagy is an evolutionarily conserved protein degradation pathway in eukaryotes, which plays a key-role in regulating protein homeostasis and which is essential for cell survival under metabolic stress. Ubiquitinated proteins are degraded by the proteasome through the ER-associated degradation pathway and by autophagy through the ER-activated autophagy pathway (67).

In addition to its role in cellular homeostasis, autophagy has been serving as a form of programmed cell death, as well as a cell-protective role in cases of nutrient deprivation (68-69). Recent studies have suggested that unfolded protein response signaling may also affect interactions within the cancer microenvironment. Unfolded protein response, autophagy and ER stress-induced apoptosis have been documented to regulate cancer cell future. Furthermore, different anti-cancer treatments may activate this signaling in tumor cells, a process that has been proposed to either enhance cancer cell death or to act as a mechanism of resistance to chemotherapy (70-72).

Recent data advocate that ER stress and autophagy may play a role in the apoptosis process, which is induced by the curcumin analogue B19 in an epithelial ovarian tumor cell line and in hepatocellular carcinoma cells and that autophagy inhibition could increase curcumin analogue-induced apoptosis by inducing severe ER stress. In other words, this curcumin analogue may induce ER-stress, autophagy and apoptosis in ovarian cancer cell lines in vitro (73-74). Other researchers have demonstrated that autophagy could act as programmed cell death type II and could efficiently suppress the growth of malignant glioma cells after curcumin treatment (75).

Curcumin Bioavailability

Curcumin lacks toxicity and has lately gained much interest as a potential anticancer agent. Its main disadvantage is its low oral bioavailability due to its extensive first-pass metabolism and its poor aqueous solubility (76-81). It is widely known that the enhanced permeability and retention effect of nanomaterials may improve the accumulation of chemotherapeutic agents at tumor sites. For example, liposomes, carbon nanotubes, dendrimers, and micelles have been used as carriers for SN38, doxorubicin, paclitaxel, and cisplatin to improve drug concentrations in tumors and reduce adverse effects (81-86). Another advantage of using nanomaterials as drug carriers is the enhanced solubility of chemotherapeutic drugs. Self-assembling peptide nanofibers have attracted much attention due to their good biocompatibility, easy modification, and design flexibility through a “bottom-up” approach (87-88). They have been widely used in various cell cultures, as well as drug delivery systems to enhance solubility of a hydrophobic drug, improve accumulation at the tumor site, and reduce adverse effects (89). Hydrophobic antitumor drugs encapsulated into peptide nanofibers, such as paclitaxel, camptothecin and ellipticine, have shown improved anticancer effects (90-92). Some studies have demonstrated that the two-dimensional structure of peptide nanofibers is superior to the three-dimensional structure of nanoparticles for drug carriers. Indeed, Law et al. demonstrated that peptide-based nanofibers have better biocompatibility, better tumor targeting within a shorter time and more rapid elimination compared with spherical nanomaterials (poly[lactic-co-glycolic acid], gold, polystyrene, cadmium and selenium quantum dots), and carbon rods (93).

Nowadays, curcumin has been much explored and various synthetic analogues have been prepared and evaluated for potential pharmacological activities (94-101). Some analogues have shown promising properties in various models and various cancer cell lines. A recent study documented that curcumin-related compounds with a benzyl piperidone have enhanced absorption and biological activities (102-103). Other studies have also demonstrated the potential anticancer properties of curcumin analogues (104-107). The incorporation of curcumin into nano-formulations for enhanced water-solubility has indeed revolutionized the bioavailability of curcumin. Nano-formulations have accomplished improved delivery and better concentrations of curcumin in the cell in vitro, while their prolonged release formulas along with their higher degree of compatibility seem to be very promising for their effects in vivo (108-110).

Conclusion

Curcumin and its analogues have been demonstrated to possess various anticancer properties in a series of cancer cell lines, such as pancreatic, lung, ovarian, oral, colorectal, breast carcinoma and even in melanoma cells. In the future, further research will ascertain or not the potential of curcumin analogues as effective chemotherapy agents.

  • Received October 10, 2014.
  • Revision received November 3, 2014.
  • Accepted November 7, 2014.
  • Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Goel A,
    2. Kunnumakkara AB,
    3. Aggarwal BB
    : Curcumin as “Curecumin”: From kitchen to clinic. Biochem Pharmacol 75: 787-809, 2008.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kim YS,
    2. Ahn Y,
    3. Hong MH,
    4. Joo SY,
    5. Kim KH,
    6. Sohn IS,
    7. Park HW,
    8. Hong YJ,
    9. Kim JH,
    10. Kim W,
    11. Jeong MH,
    12. Cho JG,
    13. Park JC,
    14. Kang JC
    : Curcumin attenuates inflammatory responses of TNF-α-stimulated human endothelial cells. J Cardiovasc Pharmacol 50: 41-49, 2007.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Da-Lozzo EJ,
    2. Moledo RC,
    3. Faraco CD,
    4. Ortolani-Machado CF,
    5. Bresolin TM,
    6. Silveira JM
    : Curcumin/xanthan galactomannan hydrogels: rheological analysis and biocompatibility. Carbohydr Polym 93: 279-284, 2013.
    OpenUrlPubMed
    1. Hsu CH,
    2. Cheng AL
    . Clinical studies with curcumin: Adv Exp Med Biol 595: 471-480, 2007.
    OpenUrlCrossRefPubMed
    1. Park W,
    2. Amin AR,
    3. Chen ZG,
    4. Shin DM
    : New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila) 6: 387-400, 2013.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Strimpakos AS,
    2. Sharma RA
    : Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10: 511-545, 2008.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Kapakos G,
    2. Youreva V,
    3. Srivastava AK
    : Cardiovascular protection by curcumin: Molecular aspects. Indian J Biochem Biophys 49: 306-315, 2012.
    OpenUrlPubMed
  6. ↵
    1. Agrawal DK,
    2. Mishra PK
    : Curcumin and its analogs: potential anti-cancer agents. Med Res Rev 30: 818-860, 2010.
    OpenUrlPubMed
    1. Du ZY,
    2. Jiang YF,
    3. Tang ZK,
    4. Mo RQ,
    5. Xue GH,
    6. Lu YJ
    : Antioxidation and tyrosinase inhibition of polyphenolic curcumin analogs. Biosci Biotechnol Biochem 75: 2351-2358, 2011.
    OpenUrlPubMed
    1. Masuda T,
    2. Maekawa T,
    3. Hidaka K,
    4. Shinohara A,
    5. Takeda Y,
    6. Yamaguchi H
    : Chemical studies on antioxidant mechanism of curcumin: analysis of oxidative coupling products from curcumin and linoleate. J Agric Food Chem 49: 2539-2547, 2001.
    OpenUrlCrossRefPubMed
    1. Menon VP,
    2. Sudheer AR
    : Anti-oxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595: 105-125, 2007.
    OpenUrlCrossRefPubMed
    1. Chainani-Wu N
    : Safety and anti-inflammatory activity of curcumin: a component of Curcuma longa. Altern Complement Med 9: 161-168, 2003.
    OpenUrl
    1. Jurenka JS
    : Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of pre-clinical and clinical research. Altern Med Rev 14: 141-153, 2009.
    OpenUrlPubMed
    1. Kuttan R,
    2. Bhanumathy P,
    3. Nirmala K,
    4. George MC
    : Potential anticancer activity of turmeric (curcuma longa). Cancer Lett 29: 197-202, 1985.
    OpenUrlCrossRefPubMed
    1. Huang MT,
    2. Smart RC,
    3. Wong CQ,
    4. Conney A
    : H. Inhibitory effect of curcumin, chlorogenic acid, caffeid acid and ferulic acid on tumor promotion in mouse skin by 12-0-tetradecanoylphorbol-13-acetate. Cancer Res 48: 5941-5946, 1988.
    OpenUrlAbstract/FREE Full Text
    1. Huang MT,
    2. Wang ZY,
    3. Georgiadis CA,
    4. Laskin JD,
    5. Conney AH
    : Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7, 12,dimethylbenz[a]nthracene. Carcinogenesis 13: 2183-2186, 1992.
    OpenUrlCrossRefPubMed
    1. Huang MT,
    2. Lou YR,
    3. Ma W,
    4. Newmark HL,
    5. Reuhi KR,
    6. Conney AH
    : Inhibitory effects of dietary curcumin in forestomach, duodenal and colon carcinogenesis in mice. Cancer Res 54: 5841-5847, 1994.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Rao CV,
    2. Rivenson A,
    3. Simi B,
    4. Reddy B
    : Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55: 259-266, 1995.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Gupta SC,
    2. Sundaram C,
    3. Reuter S,
    4. Aggarwal BB
    : Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 10-12: 775-787, 2010.
    OpenUrl
  9. ↵
    1. Sen R,
    2. Baltimore D
    : Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bharti AC,
    2. Aggarwal BB
    : Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Ann NY Acad Sci 973: 392-395, 2002.
    OpenUrlCrossRefPubMed
    1. Bharti AC,
    2. Aggarwal BB
    : Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64: 883-888, 2002.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wang CY,
    2. Mayo MW,
    3. Baldwin AS Jr.
    : TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Levy DE,
    2. Darnell JE Jr.
    : Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662, 2002.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Bharti Weber D,
    2. Shishodia S,
    3. Alexanian R,
    4. Reuben JM,
    5. Weber D,
    6. Raj-Vadhan S
    : Nuclear factor-kappaB and STAT3 are constitutively active in CD138+cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103: 3175-3184, 2004.
    OpenUrlAbstract/FREE Full Text
    1. Real PJ,
    2. Sierra A,
    3. De Juan A,
    4. Segovia JC,
    5. Lopez-Vega JM,
    6. Fernandez-Luna JL
    : Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7688, 2002.
    OpenUrlCrossRefPubMed
    1. Bhardwaj A,
    2. Sethi G,
    3. Vadhan-Raj S,
    4. Bueso-Ramos C,
    5. Takada Y,
    6. Gaur U
    : Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109: 2293-2302, 2007.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Ahn KS,
    2. Sethi G,
    3. Sung B,
    4. Yu J,
    5. Sahoo S,
    6. Meinke PT,
    7. Aggerwal BB
    : Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 68: 4406-4415, 2008.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Schlessinger K,
    2. Levy DE
    : Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 65: 5828-5834, 2005.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Gamero AM,
    2. Young HA,
    3. Wiltrout RH
    : Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 5: 111-112, 2004.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Bowman T,
    2. Garcia R,
    3. Turkson J,
    4. Jove R
    : STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kortylewski M,
    2. Kujawski M,
    3. Wang T,
    4. Wei S,
    5. Zhang S,
    6. Pilon-Tomas S
    : Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314-1321, 2005.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Catlett-Falcone R,
    2. Landowski TH,
    3. Oshiro MM,
    4. Turkson J,
    5. Levitzki A,
    6. Savino R
    : Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
    OpenUrlCrossRefPubMed
    1. Masuda M,
    2. Suzui M,
    3. Yasumatu R,
    4. Nakashima T,
    5. Kuratomi Y,
    6. Azuma K,
    7. Tomita T,
    8. Komiyama S,
    9. Weinstein IB
    : Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3355, 2002.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Zushi S,
    2. Shinomura Y,
    3. Kiyohara T,
    4. Miyazaki Y,
    5. Kondo S,
    6. Sugimachi M,
    7. Higashimoto Y,
    8. Kanayama S,
    9. Matsuzawa Y
    : STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 78: 326-330, 1998.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Huang M,
    2. Page C,
    3. Reynolds RK,
    4. Lin J
    : Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 79: 67-73, 2000.
    OpenUrlCrossRefPubMed
    1. Roder S,
    2. Steimle C,
    3. Meinhardt G,
    4. Pahl HL
    : STAT3 is constitutively active in some patients with polycythemia rubra vera. Exp Hematol 29: 694-702, 2001.
    OpenUrlCrossRefPubMed
    1. Mora LB,
    2. Buettner R,
    3. Seigne J,
    4. Diaz J,
    5. Ahmad N,
    6. Garcia R,
    7. Bowman T,
    8. Falcone R,
    9. Fairclough R,
    10. Cantor A,
    11. Muro-Cacho C,
    12. Livingston S,
    13. Karras J,
    14. Pow-Sang J,
    15. Jove R
    : Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
    OpenUrlAbstract/FREE Full Text
    1. Greten FR,
    2. Weber CK,
    3. Greten TF,
    4. et al
    . Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123: 2052-2063, 2002.
    OpenUrlCrossRefPubMed
    1. Kirito K,
    2. Nagashima T,
    3. Ozawa K,
    4. Komatsu M
    : Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells. Int J Hematol 75: 51-54, 2002.
    OpenUrlCrossRefPubMed
    1. Schaefer LK,
    2. Ren Z,
    3. Fuller GN,
    4. Schaefer TS
    : Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 21: 2058-2065, 2002.
    OpenUrlCrossRefPubMed
    1. Hsiao JR,
    2. Jin YN,
    3. Tsai ST
    : Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis. Br J Cancer 89: 344-349, 2003.
    OpenUrlCrossRefPubMed
    1. Song L,
    2. Turkson J,
    3. Karras JG,
    4. Jove R,
    5. Haura EB
    : Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22: 4150-4165, 2003.
    OpenUrlCrossRefPubMed
    1. To KF,
    2. Chan MW,
    3. Leung WK
    : Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer 91: 1335-1341, 2004.
    OpenUrlCrossRefPubMed
    1. Lin Q,
    2. Lai R,
    3. Chirieac LR,
    4. Li C,
    5. Thomazy VA,
    6. Grammatikakis I,
    7. Rassidakis GZ,
    8. Zhang W,
    9. Fujio Y,
    10. Kunisada K,
    11. Hamilton SR,
    12. Amin HM
    : Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 167: 969-980, 2005.
    OpenUrlCrossRefPubMed
    1. Rahmani AH,
    2. Al Zohairy MA,
    3. Aly SM,
    4. Khan MA
    : Curcumin: a potential candidate in prevention of cancer via modulation of molecular pathways. Biomed Res Int 2014:761608, 2014. Epub 2014 Sep 10.
    OpenUrlPubMed
  22. ↵
    1. Paul NK,
    2. Jha M,
    3. Bhullar KS,
    4. Rupasighe HP,
    5. Balzarini J,
    6. Jha A
    : All trans 1-(3-arylacryloyl)-3,5-bis (pyridine-4-ypmethylene) piperidin-4-ones as curcumin-inspired antineoplastics. Eur J Med Chem 87C: 461-470, 2014.
    OpenUrlPubMed
  23. ↵
    1. Kasdagly M,
    2. Radhakrishnan S,
    3. Reddivari L,
    4. Veeramacheni DN,
    5. Vanamala J
    : Colon carcinogenesis: Influence of Western diet-induced obesity and targeting stem cells using dietary bioactive compounds. Nutrition 11-12: 1242-1256, 2014.
    OpenUrl
  24. ↵
    1. Anthwal A,
    2. Thakur BK,
    3. Rawat MS,
    4. Rawat DS,
    5. Tyagi AK,
    6. Aggarwal BB
    : Synthesis, characterization and in vitro anticancer activity of C-5 curcumin analogues with potential to inhibit TNF-a-induced NF-kB activation. Biomed Res Int 2014: 524161, 2014.
    OpenUrlPubMed
    1. Chiablaem K,
    2. Lirdprapamongkol K,
    3. Keeratichamroen S,
    4. Surarit R,
    5. Svasti J
    : Curcumin suppresses vasculogenic mimicry capacity of hepatocellular carcinoma cells through STAT3 and PI3K/AKT inhibition. Anticancer Res 4: 1857-1864, 2014.
    OpenUrl
    1. Abdulghani J,
    2. Gu L,
    3. Dagvadorj A
    : Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 172: 1717-1728, 2008.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Chen HW,
    2. Lee JY,
    3. Huang JW,
    4. Wang CC,
    5. Chen WJ,
    6. Su SF,
    7. Huang CW,
    8. Ho CC,
    9. Chen JJ,
    10. Tsai MF,
    11. Yu SL,
    12. Yang PC
    : Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 68: 18: 7428-7438, 2008.
    OpenUrl
  26. ↵
    1. Lee JY,
    2. Lee YM,
    3. Chang GC
    : Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. PLoS ONE 6: 8, e23756, 2011.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Shishodia S,
    2. Singh T,
    3. Chaturvedi MM
    : Modulation of transcription factors by curcumin. Adv Experiment Med Biol 595: 127-148, 2007.
    OpenUrl
  28. ↵
    1. Davie JR,
    2. He S,
    3. Li L,
    4. Sekhavat A
    : Nuclear organization and chromatin dynamics–Sp1, Sp3 and histone deacetylases. Adv Enz Reg 48(1): 189-208, 2008.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Shi Q,
    2. Le X,
    3. Abbruzzese JL,
    4. Qian CN,
    5. Tang H,
    6. Xiong Q,
    7. Wang B,
    8. Li XC,
    9. Xie K
    : Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61(10): 4143-4154, 2001.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Zannetti A,
    2. Del Vecchio S,
    3. Carriero MV,
    4. Fonti R,
    5. Franco P,
    6. Botti G,
    7. D'Aiuto G,
    8. Stoppelli MP,
    9. Salvatore M
    : Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 60(6): 1546-1551, 2000.
    OpenUrlAbstract/FREE Full Text
    1. Kitadai Y,
    2. Yasui W,
    3. Yokozaki H
    : The level of a transcription factor Sp1 is correlated with the expression of EGF receptor in human gastric carcinomas. Bioch Biophys Res Commun 189(3): 1342-1348, 1992.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Leupold JH,
    2. Yang HS,
    3. Colburn NH
    : Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 26(31): 4550-4562, 2007.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Cho SG,
    2. Yi Z,
    3. Pang X
    : Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res 69(17): 7062-7070, 2009.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Chadalapaka G,
    2. Jutooru I,
    3. Chintharlapalli S,
    4. Papineni S,
    5. Smith R 3rd.,
    6. Li X,
    7. Safe S
    : Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res 68(13): 5345-5354, 2008.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Aigner S,
    2. Ramos CL,
    3. Hafezi-Moghadam A
    : CD24 mediates rolling of breast carcinoma cells on P-selectin. The FASEB J 12(12): 1241-1251, 1998.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Lou Z,
    2. O'Reilly S,
    3. Liang H
    : Down-regulation of overexpression Sp1 protein in human fibrosarcoma cell lines inhibits tumor formation. Cancer Res 65(3): 1007-1017, 2005.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Chen CC,
    2. Sureshbabul M,
    3. Chen HW
    : Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer. Evidence-Based Complem Altern Med 2013: e541685, 2013.
    OpenUrl
  37. ↵
    1. Zhou DY,
    2. Zhang K,
    3. Conney AH
    : Synthesis and Evaluation of Curcumin-Related Compounds Containing Benzyl Piperidone for Their Effects on Human Cancer Cells. Chem Pharm Bull 65(11): 1149-1155, 2013.
    OpenUrl
  38. ↵
    1. Clarke R,
    2. Cook KL,
    3. Hu R,
    4. Tavassoly I,
    5. Schwartz JL,
    6. Baumann WT,
    7. Tyson JJ,
    8. Xuan J,
    9. Wang Y,
    10. Wärri A,
    11. Shajahan AN
    : Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res 72: 1321-1331, 2012.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Duprez J,
    2. Jonas JC
    : Role of activating transcription factor 3 in low glucose- and thapsigargin-induced apoptosis in cultured mouse islets. Biochem Biophys Res Commun 415: 294-299, 2011.
    OpenUrlPubMed
  40. ↵
    1. Zhang K,
    2. Kaufman RJ
    : From endoplasmic-reticulum stress to the inflammatory response. Nature 454: 455-462, 2008.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Marciniak SJ,
    2. Ron D
    : Endoplasmic reticulum stress signaling in disease. Physiol Rev 86: 1133-1149, 2006.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Carew JS,
    2. Nawrocki ST,
    3. Cleveland JL
    : Modulating autophagy for therapeutic benefit. Autophagy 3: 464-467, 2007.
    OpenUrlCrossRefPubMed
    1. Dalby KN,
    2. Tekedereli I,
    3. Lopez-Berestein G,
    4. Ozpolat B
    : Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6: 322-329, 2010.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Qu W,
    2. Xiao J,
    3. Zhang H
    : B19, a Novel Monocarbonyl Analogue of Curcumin, Induces Human Ovarian Cancer Cell Apoptosis via Activation of Endoplasmic Reticulum Stress and the Autophagy Signaling Pathway. Intern J Biol Sci 9(8): 766-777, 2013.
    OpenUrl
  44. ↵
    1. Grabacka MM,
    2. Gawin M,
    3. Pierzchlska M
    : Phytochenical modulators of mitochondria: the search for chemopreventive agents and supportive therapeutics. Pharmaceuticals (Basel) 7(9): 913-942, 2014.
    OpenUrlPubMed
  45. ↵
    1. Zhou T,
    2. Ye L,
    3. Bai Y,
    4. Sun A,
    5. Cox B,
    6. Liu D,
    7. Liotta D,
    8. Snyder JP,
    9. Fu H,
    10. Huang B
    : Autophagy and apoptosis in hepatocellular carcinoma induced by EF-(GSH)2: A novel curcumin analog. PLoSOne 9(9): e107876, 2014.
    OpenUrl
  46. ↵
    1. Aoki H,
    2. Takada Y,
    3. Kondo S
    : Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72: 29-39, 2007.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Dhillon N,
    2. Aggarwal BB,
    3. Newman RA
    : Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499, 2008.
    OpenUrlAbstract/FREE Full Text
    1. Zlotogorski A,
    2. Dayan A,
    3. Dayan D
    : Nutraceuticals as new treatment approaches for oral cancer I: Curcumin. Oral Oncol 49: 187-191, 2013.
    OpenUrlCrossRefPubMed
    1. Adams BK,
    2. Ferstl EM,
    3. Davis MC
    : Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenic agents. Bioorg Med Chem 12: 3871-3883, 2004.
    OpenUrlCrossRefPubMed
    1. Lee KH,
    2. Ab Aziz FH,
    3. Syahida A
    : Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for anti-inflammatory, anti-oxidant and anti-tyrosinase activities. Eur J Med Chem 44: 3195-3200, 2009.
    OpenUrlPubMed
    1. Zhao C,
    2. Yang J,
    3. Wang Y
    : Synthesis of mono-carbonyl analogues of curcumin and their effects on inhibition on cytokine release in LPS-stimulated raw macrophages. Bioorg Med Chem 18: 2388-2393, 2010.
    OpenUrlPubMed
  48. ↵
    1. Bala V,
    2. Rao S,
    3. Boyd BJ,
    4. Prestidge CA
    : Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release 172(1): 48-61, 2013.
    OpenUrlCrossRefPubMed
    1. Das M,
    2. Singh RP,
    3. Datir SR,
    4. Jain S
    : Intranuclear drug delivery and effective in vivo cancer therapy via estradiol-PEG-appended multiwalled carbon nanotubes. Mol Pharm August 19, 2013. [Epub ahead of print.]
    1. Teow HM,
    2. Zhou Z,
    3. Najlah M,
    4. Yusof SR,
    5. Abbott NJ,
    6. D'Emanuele A
    : Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int J Pharm 441(1-2): 701-711, 2013.
    OpenUrlCrossRefPubMed
    1. Qi X,
    2. Li N,
    3. Gu H
    : Amphiphilic oligomer-based micelles as cisplatin nanocarriers for cancer therapy. Nanoscale 5(19): 8925-8929, 2013.
    OpenUrlPubMed
    1. Arzuman L,
    2. Beale P,
    3. Chan C,
    4. Yu JQ,
    5. Huq F
    : Synergism from combinations of tris(benzimidazole) monochloro-platinum(II) chloride with capsaicin, quercetin, curcumin and cisplatin in human ovarian cancer cell lines. Anticancer Res 34(10): 5463-5464, 2014.
    OpenUrl
  49. ↵
    1. Huq F,
    2. Yu JQ,
    3. Beale P,
    4. Chan C,
    5. Arzuman L,
    6. Nessa MU,
    7. Mazumder ME
    : Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer. Anticancer Res 34(1): 541-545, 2014.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Nune M,
    2. Kumaraswamy P,
    3. Krishnan UM,
    4. Sethuraman S
    : Self-assembling peptide nanofibrous scaffolds for tissue engineering: novel approaches and strategies for effective functional regeneration. Curr Protein Pept Sci 14(1): 70-84, 2013.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Hu Y,
    2. Wang H,
    3. Wang J
    : Supramolecular hydrogels inspired by collagen for tissue engineering. Org Biomol Chem 8(14): 3267-3271, 2010.
    OpenUrlPubMed
  52. ↵
    1. Wang H,
    2. Wei J,
    3. Yang C
    : The inhibition of tumor growth and metastasis by self-assembled nanofibers of Taxol. Biomaterials 33(24): 5848-5853, 2012.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Zhang P,
    2. Cheetham AG,
    3. Lin YA,
    4. Cui H
    : Self-assembled Tat nanofibers as effective drug carrier and transporter. ACS Nano 7(7): 5965-5977, 2013.
    OpenUrlCrossRefPubMed
    1. Soukasene S,
    2. Toft DJ,
    3. Moyer TJ
    : Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin. ACS Nano 5(11): 9113-9121, 2011.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Cho H,
    2. Indig GL,
    3. Weichert J,
    4. Shin HC,
    5. Kwon GS
    : In vivo cancer imaging by poly(ethylene glycol)-b-poly(varepsilon-caprolactone) micelles containing a near-infrared probe. Nanomedicine 8(2): 228-236, 2012.
    OpenUrlPubMed
  55. ↵
    1. Wagh A,
    2. Singh J,
    3. Qian S,
    4. Law B
    : A short circulating peptide nanofiber as a carrier for tumoral delivery. Nanomedicine 9(4): 449-457, 2013.
    OpenUrlPubMed
  56. ↵
    1. Yadav B,
    2. Taurin S,
    3. Rosengren RJ
    : Synthesis and cytotoxic potential of heterocyclic cyclohexanone analogues of curcumin. Bioorg Med Chem 18: 6701-6707, 2010.
    OpenUrlCrossRefPubMed
    1. Sun A,
    2. Shoji M,
    3. Lu YJ,
    4. Liotta DC,
    5. Snyder JP
    : Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 49: 3153-3158, 2006.
    OpenUrlCrossRefPubMed
    1. Somers-Edgar TJ,
    2. Taurin S,
    3. Larsen L
    : Mechanisms of the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen-receptor negative human breast cancer cell lines. J Invest New Drugs 29: 87-97, 2011.
    OpenUrl
    1. Robinson TP,
    2. Ehlers T,
    3. Hubbard RB IV.
    : Design, synthesis and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg Med Chem Lett 13: 115-117, 2003.
    OpenUrlCrossRefPubMed
    1. Ohori H,
    2. Yamakoshi H,
    3. Tomizawa M
    : Synthesis and biological analysis of new curcumin analogues baring an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther 5: 2563-2571, 2006.
    OpenUrlAbstract/FREE Full Text
    1. Subramaniam D,
    2. May R,
    3. Sureban SM
    : Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 68: 1962-1969, 2008.
    OpenUrlAbstract/FREE Full Text
    1. Liang G,
    2. Shao L,
    3. Wang Y
    : Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 17: 2623-2631, 2009.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Karthikeyan NS,
    2. Sathiyanarayanan KI,
    3. Aravindan PG,
    4. Giridharan P
    : Synthesis, crystal structure and anti-cancer properties of cyclic monocarbonyl analogs of curcumin. Med Chem Res 20: 81-87, 2011.
    OpenUrl
  58. ↵
    1. Dayton A,
    2. Selvendiran K,
    3. Kuppusamy ML
    : Cellular uptake, retention and bioabsorption of HO-3867, a fluorinated curcumin analog with potential antitumor properties. Cancer Biol Ther 10: 1027-1032, 2010.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Lee HE,
    2. Choi ES,
    3. Jung JY
    : Inhibition of specificity protein 1 by dibenzylideneacetone, a curcumin analogue, induces apoptosis in mucoepidermoid carcinomas and tumor xenografts through Bim and truncated Bid. Oral Oncol. pii: S1368-8375(13)00748-3. doi: 10.1016/j.oraloncology.2013.11.006. [Epub ahead of print]
  60. ↵
    1. Novaković M,
    2. Pešić M,
    3. Trifunović S
    : Diarylheptanoids from the bark of black alder inhibit the growth of sensitive and multi-drug resistant non-small cell lung carcinoma cells. Phytochemistry 97:46-54, 2014. doi: 0.1016/j.phytochem. 2013.11.001. Epub 2013 Nov 28.
    OpenUrlPubMed
    1. Zheng A,
    2. Li H,
    3. Wang X
    : Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction. Curr Cancer Drug Targets. 2013; Nov 25. [Epub ahead of print].
    1. Ucisik MH,
    2. Kupsu S,
    3. Schuster B,
    4. Sleytr UB
    : Characterization of CurcuEmulsomes: nanoformulation for enhanced solubility and delivery of curcumin. J Nanobiotechnol 11: 37, 2013.
    OpenUrlCrossRef
  61. ↵
    1. Sahu A,
    2. Kaoju N,
    3. Goswami P,
    4. Bora U
    : Encapsulation of curcumin in Pluronic block polymer micelles for drug delivery appliacations. J Biomater Appl 25: 619-639, 2011.
    OpenUrlCrossRefPubMed
  62. ↵
    1. Basniwal RK,
    2. Khosia R,
    3. Jain N
    : Improving the anticancer activity of curcumin using nanocurcumin dispersion in water. Nutr Cancer 66(6): 1015-1022, 2014.
    OpenUrlPubMed
    1. Esmaili M,
    2. Ghaffari SM,
    3. Moosavi-Movahedi Z
    : Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food industry application. Lwt Food Sci Technol 44: 2166-2172, 2011.
    OpenUrl
  63. ↵
    1. Anuchapreeda S,
    2. Fukumori Y,
    3. Okonogi S,
    4. Ichikawa H
    : Preparation of Lipid Nanoemulsions Incorporating Curcumin for Cancer Therapy. J Nanotechnology 1-11, 2012.
PreviousNext
Back to top

In this issue

Anticancer Research: 35 (2)
Anticancer Research
Vol. 35, Issue 2
February 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Potential Anticancer Properties and Mechanisms of Action of Curcumin
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 14 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Potential Anticancer Properties and Mechanisms of Action of Curcumin
NATALIA G. VALLIANOU, ANGELOS EVANGELOPOULOS, NIKOS SCHIZAS, CHRISTOS KAZAZIS
Anticancer Research Feb 2015, 35 (2) 645-651;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Potential Anticancer Properties and Mechanisms of Action of Curcumin
NATALIA G. VALLIANOU, ANGELOS EVANGELOPOULOS, NIKOS SCHIZAS, CHRISTOS KAZAZIS
Anticancer Research Feb 2015, 35 (2) 645-651;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Curcumin's Mechanisms of Action: The Role of STAT3 and NF-κB
    • Curcumin and Other Transcription Factors
    • Curcumin and Sp-1
    • Curcumin and Adhesion Molecules
    • Curcumin, Endoplasmic Reticulum Stress and Autophagy
    • Curcumin Bioavailability
    • Conclusion
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Gene Expression Mediated Antiproliferative Potential and Safety of Selected Medicinal Plants Against Cancerous and Normal Cells
  • Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential
  • Curcumin exerts a protective effect against premature ovarian failure in mice
  • Enhancement of Cytotoxicity of Three Apoptosis-inducing Agents Against Human Oral Squamous Cell Carcinoma Cell Line by Benzoxazinotropone
  • Google Scholar

More in this TOC Section

  • Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10
  • Proteolytic Enzyme Therapy in Complementary Oncology: A Systematic Review
  • Multimodal Treatment of Primary Advanced Ovarian Cancer
Show more Reviews

Similar Articles

Keywords

  • Curcumin
  • anti-cancer properties
  • Autophagy
  • transcription factors
  • bioavailability
  • review
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire